Affluent Medical SA (0JZ) Price & Analysis

0 Followers

0JZ Stock Chart & Stats

€3.06

-€0.04(-2.55%)

At close: Jan 08 4:00 PM EST

€3.06

-€0.04(-2.55%)

Day’s Range― - ―

52-Week Range€1.25 - €7.20

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€398.37M

Enterprise Value€164.42M

Total Cash (Recent Filing)€1.76M

Total Debt (Recent Filing)€24.04M

Price to Earnings (P/E)―

Beta0.02

Next Earnings

Sep 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.64

Shares Outstanding62,269,176

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)12.26

Price to Sales (P/S)0.00

P/FCF Ratio-5.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€5.00

Price Target Upside63.40% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.47

Revenue Forecast (FY)€1.72M

Bulls Say, Bears Say

Bulls Say

Diverse Clinical-stage PipelineAffluent’s portfolio spans structural heart, vascular and urology devices, spreading scientific and commercial risk across multiple programs. Multiple development-stage candidates create several independent regulatory and partnerable milestones, improving long-term optionality for commercialization.

Substantial Asset BaseReportedly substantial assets provide tangible collateral and R&D capacity that can support continued development or be used in financing/partnership transactions. A meaningful asset base preserves strategic flexibility even as equity compresses, enabling non-dilutive options like asset-backed deals.

Clear Regulatory/commercial PathwayThe company’s explicit focus on progressing candidates through clinical and regulatory channels and pursuing licensing or distribution partnerships represents a coherent commercialization strategy. This structured pathway aligns incentives for milestone-driven value creation and external partner interest.

Bears Say

Zero 2025 Revenue And Widening LossesReporting zero annual revenue in 2025 and materially wider losses demonstrates the company remains pre-revenue and far from operating leverage. Persistent negative gross profit undermines the path to self-sustaining margins and increases the likelihood of prolonged external funding needs.

Deteriorated LeverageRising debt alongside collapsing equity elevates refinancing and solvency risk, reducing financial flexibility to invest in trials or scale commercialization. Higher leverage increases fixed obligations and can force costly or dilutive financing, constraining strategic choices over months ahead.

Persistent Heavy Cash BurnConsistent negative operating and free cash flow, worsening in 2025, implies the company cannot internally fund development. Dependence on external financing raises dilution and execution risk, and may delay trials or regulatory timelines if new capital is constrained.

Affluent Medical SA News

ODDO BHF Launches Outperformance Coverage on Carvolix, Signaling Strong Upside Potential

Affluent Medical SA ( ($FR:CVX) ) has shared an announcement. Carvolix has gained fresh attention in the equity...

4d ago

Affluent Medical Strengthens Leadership Team to Drive Market Access

Affluent Medical SA ( ($FR:AFME) ) has shared an announcement. Affluent Medical has announced key leadership appointments to...

1y ago

Affluent Medical Strengthens Board with Industry Veteran Liane Teplitsky

Affluent Medical SA ( ($FR:AFME) ) has issued an announcement. Affluent Medical has appointed Liane Teplitsky, a seasoned...

1y ago

Affluent Medical Discloses Share Capital and Voting Rights Details

An announcement from Affluent Medical SA ( ($FR:AFME) ) is now available. Affluent Medical has disclosed the number...

1y ago

Affluent Medical Completes Pilot Phase of Artus Urinary Sphincter Study

Affluent Medical SA ( ($FR:AFME) ) has issued an update. Affluent Medical has achieved a significant milestone by...

2y ago

Affluent Medical Reports Half-Year Liquidity Contract Update

Affluent Medical SA ( ($FR:AFME) ) just unveiled an announcement. Affluent Medical has released its half-year liquidity contract...

2y ago

Affluent Medical Announces Share and Voting Rights Details

Affluent Medical SA ( ($FR:AFME) ) just unveiled an update. Affluent Medical announced the total number of shares...

2y ago

Affluent Medical Enhances Share Liquidity with New Contract

Affluent Medical SA (FR:AFME) has released an update. Affluent Medical has initiated a new liquidity contract with Rothschild...

2y ago

Affluent Medical SA Gears Up for Scientific Showcases

Affluent Medical SA (FR:AFME) has released an update. Affluent Medical SA, a French medical technology company, is set...

2y ago

Affluent Medical Targets 2026 Market Entry

Affluent Medical SA (FR:AFME) has released an update. Affluent Medical, a French medtech firm, has detailed its share...

2y ago

0JZ FAQ

What was Affluent Medical SA’s price range in the past 12 months?

Affluent Medical SA lowest stock price was €1.25 and its highest was €7.20 in the past 12 months.

What is Affluent Medical SA’s market cap?

Affluent Medical SA’s market cap is €398.37M.

When is Affluent Medical SA’s upcoming earnings report date?

Affluent Medical SA’s upcoming earnings report date is Sep 24, 2026 which is in 53 days.

How were Affluent Medical SA’s earnings last quarter?

Currently, no data Available

Is Affluent Medical SA overvalued?

According to Wall Street analysts Affluent Medical SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Affluent Medical SA pay dividends?

Affluent Medical SA does not currently pay dividends.

What is Affluent Medical SA’s EPS estimate?

Affluent Medical SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Affluent Medical SA have?

Affluent Medical SA has 62,269,176 shares outstanding.

What happened to Affluent Medical SA’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Affluent Medical SA?

Currently, no hedge funds are holding shares in DE:0JZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Affluent Medical SA

Carvolix S.A. operates as a medical technology firm, concurrently involved in both commercialization and clinical development, specializing in treatment solutions for structural heart ailments and cerebral strokes. The company's innovative endeavors encompass the creation of AI- and imaging-driven mini-robots, engineered for executing intricate medical procedures, as well as the development of biomimetic heart valves. Established on January 30, 2026, Carvolix S.A. maintains its headquarters in Aix-en-Provence, France.

Affluent Medical SA (0JZ) Earnings & Revenues

Historic Earnings Reports

0JZ Stock 12 Month Forecast

Average Price Target

€5.00

▲(63.40% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","3":"€3","6":"€6","1.5":"€1.5","4.5":"€4.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.5,3,4.5,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.34,3.4676923076923076,3.5953846153846154,3.723076923076923,3.850769230769231,3.9784615384615387,4.1061538461538465,4.233846153846153,4.361538461538462,4.489230769230769,4.616923076923078,4.7446153846153845,4.872307692307692,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.34,3.4676923076923076,3.5953846153846154,3.723076923076923,3.850769230769231,3.9784615384615387,4.1061538461538465,4.233846153846153,4.361538461538462,4.489230769230769,4.616923076923078,4.7446153846153845,4.872307692307692,{"y":5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.34,3.4676923076923076,3.5953846153846154,3.723076923076923,3.850769230769231,3.9784615384615387,4.1061538461538465,4.233846153846153,4.361538461538462,4.489230769230769,4.616923076923078,4.7446153846153845,4.872307692307692,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.29,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.65,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.65,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.79,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.43,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >